<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A number of Ags which was recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes that the autologous serum has recognized.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes that the autologous serum is able to recognize.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Exactly how specific splice sites were recognized during the processing of complex precursor messenger RNAs is not clear.</text>
                    <arg n="1">splice sites</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Most regulators belonging to the AraC/XylS family can recognize multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>The STAT1 N-terminus were recognized by A monoclonal antibody purchasing from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>The eukaryotic upstream binding factor (UBF), recognized the ribosomal RNA gene promoter and activated transcription mediated by RNA polymerase I through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>The sequence(YPYDVPDYA) at a 1:500 dilution is recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that blots were probed with.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>The sequence(YPYDVPDYA) at a 1:500 dilution is recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that blots were probed with.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>These bands can be detected with four different specific antibodies that recognized the different nonmuscle myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and make the RNA-splicing apparatus not to recognized the normal splice junction properly.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes which were recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="GREC" no="1">
                    <text>Most regulators belonging to the AraC/XylS family recognize multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and prevent the RNA-splicing apparatus from properly recognizing the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A monoclonal antibody can recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A monoclonal antibody will recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Anti-64kD human autoantigen D1 antibodies are able to recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Anti-64kD human autoantigen D1 antibodies will recognize a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Blots were probed with A monoclonal antibody that can recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Blots were probed with a monoclonal antibody that can recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognizes the epitopes in the C-terminus of LMP-1 at a 1:200 dilution, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognizes the epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Blots were probed with the proteins recognizing short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Blots were probed with the proteins that recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Blots were probed with the proteins that recognizes the short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>C-terminus of CD40 at a 1:500 dilution are recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>C-terminus of CD40 at a 1:500 dilution recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>C-terminus of CD40 at a 1:500 dilution which can be recognized by rabbit polyclonal anti-CD40 antiserum are indicated.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>C-terminus of CD40 at a 1:500 dilution, cannot be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>C-terminus of CD40 at a 1:500 dilution, could not be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>C-terminus of CD40 at a 1:500 dilution, will not be recognized in the immunoprecipitaiton with rabbit polyclonal anti-CD40 antiserum as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody has recognized the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody recognize the STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that Most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that affinity-purified polyclonal anti-LMP-1 antiserum recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that four different specific antibodies recognize the different nonmuscle myosin heavy chain isoforms (A and B).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that rabbit polyclonal anti-CD40 antiserum recognized C-terminus of CD40 at a 1:500 dilution.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that this antibody in PKR+/+MEFs recognized The two forms of Stat3 (Stat3fm and Stat3sm).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where C-terminus of CD40 at a 1:500 dilution are recognized by rabbit polyclonal anti-CD40 antiserum.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where The two forms of Stat3 (Stat3fm and Stat3sm) are recognized by this antibody in PKR+/+MEFs.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle were recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where epitopes in the C-terminus of LMP-1 at a 1:200 dilution were recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where sequence(YPYDVPDYA) at a 1:500 dilution are recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where two sites in tsx-p2 are recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody which recognizes the STAT1 N-terminus, and by western blotting</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with Most regulators belonging to the AraC/XylS family which recognizes multiple binding sites, and by western blotting</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with The NarL protein which recognized heptamers in other arrangements, and by western blotting</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with The NarL protein which recognizes heptamers in other arrangements, and by western blotting</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) which recognizes sequence(YPYDVPDYA) at a 1:500 dilution, and by western blotting</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-Stat3 pAb which recognized The lower form of Stat3, Stat3Beta, and by western blotting</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with four different specific antibodies which recognizes the different nonmuscle myosin heavy chain isoforms (A and B), and by western blotting</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex which recognized two sites in tsx-p2, and by western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex which recognized two sites in tsx-p2, and by western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with this antibody in PKR+/+MEFs which recognizes The two forms of Stat3 (Stat3fm and Stat3sm), and by western blotting</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Most regulators belonging to the AraC/XylS family recognize specifically multiple binding sites.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>The NarL protein recognized heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>The The two forms of Stat3 (Stat3fm and Stat3sm) is recognized by this antibody in PKR+/+MEFs that blots were probed with.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>The lower form of Stat3, Stat3Beta recognized by anti-Stat3 pAb are indicated.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>The the different nonmuscle myosin heavy chain isoforms (A and B) is recognized by four different specific antibodies that blots were probed with.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm), is not recognized in the immunoprecipitaiton with this antibody in PKR+/+MEFs as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>These bands can be detected with A monoclonal antibody that recognize the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>These bands can be detected with A monoclonal antibody which have recognized the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>These bands can be detected with A monoclonal antibody which recognize the STAT1 N-terminus</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies recognizing a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies that recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>These bands can be detected with Anti-64kD human autoantigen D1 antibodies which have recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>These bands can be detected with Most regulators belonging to the AraC/XylS family that recognized multiple binding sites</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>These bands can be detected with The NarL protein which have recognized heptamers in other arrangements</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>These bands can be detected with anti-Stat3 pAb that recognize The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>These bands can be detected with anti-Stat3 pAb that recognized The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>These bands can be detected with anti-Stat3 pAb that recognized The lower form of Stat3, Stat3Beta</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum which have recognized C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>These bands can be detected with rabbit polyclonal anti-CD40 antiserum which recognize C-terminus of CD40 at a 1:500 dilution</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>These bands can be detected with the cAMP-CRP activator complex recognizing two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>These bands can be detected with the cAMP-CRP activator complex that recognized two sites in tsx-p2</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs which recognize The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs which recognize The two forms of Stat3 (Stat3fm and Stat3sm)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>We show that A monoclonal antibody recognized the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>We show that A monoclonal antibody will recognize the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>We show that Anti-64kD human autoantigen D1 antibodies recognized a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>We show that Most regulators belonging to the AraC/XylS family recognizes multiple binding sites that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognized sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>We show that a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognizes sequence(YPYDVPDYA) at a 1:500 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>We show that a monoclonal antibody will recognize the STAT1 N-terminus that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>We show that affinity-purified polyclonal anti-LMP-1 antiserum recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>We show that four different specific antibodies will recognize the different nonmuscle myosin heavy chain isoforms (A and B) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>We show that the proteins will recognize short motifs within the protected region that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>We show that this antibody in PKR+/+MEFs has recognized The two forms of Stat3 (Stat3fm and Stat3sm) that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) recognize sequence(YPYDVPDYA) at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that have been recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle that will be recognized by Anti-64kD human autoantigen D1 antibodies are indicated.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, is not recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle, will not be recognized in the immunoprecipitaiton with Anti-64kD human autoantigen D1 antibodies as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>a monoclonal antibody can recognize the STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>a monoclonal antibody will binds to these 7-2-7 sites but, unlike NarP, will also recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>a monoclonal antibody will binds to these 7-2-7 sites but, unlike NarP, will also recognize the STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum have recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>affinity-purified polyclonal anti-LMP-1 antiserum will recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>anti-Stat3 pAb will binds to these 7-2-7 sites but, unlike NarP, will also recognize The lower form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>epitopes in the C-terminus of LMP-1 at a 1:200 dilution were recognized by affinity-purified polyclonal anti-LMP-1 antiserum.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>four different specific antibodies are able to recognize the different nonmuscle myosin heavy chain isoforms (A and B) in the regulated promoters.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>four different specific antibodies which has recognized the different nonmuscle myosin heavy chain isoforms (A and B) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>four different specific antibodies which has recognized the different nonmuscle myosin heavy chain isoforms (A and B) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>heptamers in other arrangements are recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>heptamers in other arrangements that will be recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>heptamers in other arrangements that will be recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>heptamers in other arrangements were recognized by The NarL protein.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>heptamers in other arrangements which were recognized by The NarL protein are indicated.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>heptamers in other arrangements, has not been recognized in the immunoprecipitaiton with The NarL protein as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>multiple binding sites, could not be recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>multiple binding sites, is not recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>multiple binding sites, was not recognized in the immunoprecipitaiton with Most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution are recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim).</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>sequence(YPYDVPDYA) at a 1:500 dilution that will be recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) are indicated.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>short motifs within the protected region that have been recognized by the proteins are indicated.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>the STAT1 N-terminus that were recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>the STAT1 N-terminus which can be recognized by a monoclonal antibody are indicated.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>the STAT1 N-terminus which were recognized by A monoclonal antibody are indicated.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>the cAMP-CRP activator complex also binds to these 7-2-7 sites but, unlike NarP, also recognizes two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>the cAMP-CRP activator complex which recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>the cAMP-CRP activator complex will recognize two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>the different nonmuscle myosin heavy chain isoforms (A and B) were recognized by four different specific antibodies.</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>the proteins has also bound to these 7-2-7 sites but, unlike NarP, has also recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>the proteins recognize short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>the proteins recognized short motifs within the protected region in the regulated promoters.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>the proteins recognized specifically short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>this antibody in PKR+/+MEFs are able to recognize The two forms of Stat3 (Stat3fm and Stat3sm) in the regulated promoters.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>this antibody in PKR+/+MEFs which has recognized The two forms of Stat3 (Stat3fm and Stat3sm) was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>two sites in tsx-p2 that will be recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>two sites in tsx-p2 which were recognized by the cAMP-CRP activator complex are indicated.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>two sites in tsx-p2, has not been recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>two sites in tsx-p2, is not recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A number of Ags that have been recognized by class I-restricted melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A number of Ags, is not recognized in the immunoprecipitaiton with class I-restricted melanoma-specific T cells as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that can recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that can recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that can recognize A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Blots were probed with class I-restricted melanoma-specific T cells that recognized A number of Ags.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Blots were probed with the RNA-splicing apparatus that can recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Blots were probed with the autologous serum recognizing the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Blots were probed with the autologous serum that can recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Blots were probed with the autologous serum that recognizes the the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>COOH-terminal epitopes, has not been recognized in the immunoprecipitaiton with either of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus are able to recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA-splicing apparatus recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum are able to recognize the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>The the epitopes is recognized by the autologous serum that blots were probed with.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>The the normal splice junction is recognized by the RNA-splicing apparatus that blots were probed with.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>These bands can be detected with the autologous serum which recognize the epitopes</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>We show that either of two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>class I-restricted melanoma-specific T cells recognize A number of Ags in the regulated promoters.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>class I-restricted melanoma-specific T cells which has recognized A number of Ags was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>class I-restricted melanoma-specific T cells which recognizes A number of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>either of two monoclonal antibodies recognizing COOH-terminal epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>either of two monoclonal antibodies which has recognized COOH-terminal epitopes was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>either of two monoclonal antibodies will binds to these 7-2-7 sites but, unlike NarP, will also recognize COOH-terminal epitopes.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>the RNA-splicing apparatus recognized the normal splice junction in the regulated promoters.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>the autologous serum are able to recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>the autologous serum can recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>the autologous serum has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>the autologous serum has also bound to these 7-2-7 sites but, unlike NarP, has also recognized the epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>the autologous serum will recognize the epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>the normal splice junction are recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>the normal splice junction recognized by the RNA-splicing apparatus are indicated.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
